Tuesday, July 24, 2012

Abandon Gastric Banding Bariatric Surgery, Say Experts


Kate Johnson
July 16, 2012 (San Diego, California) — Bariatric surgeons should abandon gastric banding in favor of sleeve gastrectomy or gastric bypass procedures, several researchers reported here at the American Society for Metabolic and Bariatric Surgery 29th Annual Meeting.
In the United States, the use of gastric banding is still "peaking," but elsewhere in the world it has largely fallen out of favor, said Michel Gagner, MD, in an interview with Medscape Medical News.
Dr. Gagner, from Hôpital du Sacré-Coeur in Montreal, Quebec, Canada, is a world-renowned bariatric surgeon who has established several bariatric surgery centers of excellence in the United States. He said he has virtually abandoned gastric banding, and performs sleeve gastrectomy in 90% of his cases.
His approach matches that of Luigi Angrisani, MD, director of the general and laparoscopic surgery unit at Giovanni Bosco Hospital in Naples, Italy.
Dr. Angrisani presented 10-year follow-up data from a prospective randomized trial comparing gastric bypass with banding, and said the evidence is clearly in favor of bypass.
"There is no point in doing further study comparing bypass with banding at this point," he told meeting attendees. "If you consider the revisions and the failures, only 26% of the banding patients had the band successfully implanted and a successful weight loss," he told Medscape Medical News in an interview. "That is not a nice result."
The study by Dr. Angrisani and colleagues involved 51 patients who were randomized from January to November 2000 to either laparoscopic adjustable gastric banding or laparoscopic Roux-en-Y gastric bypass.
In the banding group, mean age was 33.3 years and mean body mass index (BMI) was 43.4 kg/m²; in the bypass group, mean age was 34.7 years and mean BMI was 43.8 kg/m².
Of the 27 banding patients, 3 had hypertension and 1 had sleep apnea. Of the 24 bypass patients, 2 had hyperlipidemia, 1 had hypertension, and 1 had type 2 diabetes.
Ten years after surgery, 81.4% of the banding group and 87.5% of the bypass group remained in follow-up, reported Dr. Angrisani.
Of the 22 remaining banding patients, 9 (41%) had had their bands removed, leaving 13 for weight-loss evaluation.
The BMI of 6 of these 13 patients exceeded 35 kg/m², so the procedures were considered "failures"; only 7 patients in the banding group were successful in losing weight, he said.
In contrast, of the remaining 21 bypass patients, mean BMI dropped from 43.8 to 30.4 kg/m²; only 20% of the procedures in this group were considered failures.
There were no deaths in the study, and improvement in baseline comorbidities was similar in the 2 groups. However, reoperation rates were higher in the banding group than in the bypass group (41% vs 29%).
In the banding group, reasons for reoperation were pouch dilations (n = 3), band migration (n = 1), unsatisfactory weight loss (n = 4), and untreatable reflux (n = 1).
Reasons for reoperation in the bypass group were potentially life-threatening, said Dr. Angrisani — internal hernia (n = 1), cholecystectomy (n = 4), and incisional hernia (n = 1).
"The complications of bypass are iatrogenic," he told Medscape Medical News. "There is inadvertent bowel injury during manipulation of the bowel. When you do banding, you do not manipulate the bowel."
Like Dr. Gagner, Dr. Angrisani has virtually abandoned gastric banding, reserving it for a select group of smaller patients. An analysis of the Bariatric Outcomes Longitudinal Database (BOLD), presented separately at the meeting (as reported by Medscape Medical News), showed that from 2007 to 2010, banding and bypass surgery were performed in almost equal numbers in 540 hospitals in the United States (117,365 vs 138,222).
Europeans are ahead of the game, having started banding procedures before North America, and therefore detecting problems earlier, said Dr. Angrisani. "This is a very common story. While we as Europeans accept the messages from the US world of surgery, the US community does not accept data coming from Europe. So they are now living the experience we had in the last few years."
"It's a complete disaster, when you think that banding in the United States, based on the BOLD data, is the second-most common procedure," said Dr. Gagner. "Europeans are abandoning banding and the Americans are not getting the message. This abandonment that we see in Europe — we are probably going to see this in the next few years in the United States."
Although there is already a trend toward replacing banding with sleeve gastrectomy, lack of insurance coverage for the sleeve procedure remains a major barrier, he said. In the BOLD analysis, 21% of sleeve procedures were self-paid, compared with 5.7% of band procedures and 1.9% of bypass procedures.
"The European experience is more mature than the US experience with gastric banding," agreed John Morton, MD, from Stanford University in California, who reported the BOLD data at the meeting.
In an email to Medscape Medical News, Dr. Morton said that "although 6-year data for sleeve gastrectomy indicate that it is safe and effective, the potential long-term complications for the sleeve may not be fully apparent yet, and gastric banding may still be preferred due to it's favorable short-term safety profile."
Dr. Angrisani has disclosed no relevant financial relationships. Dr. Gagner reports being a speaker for Covidien, Ethicon, and Gore. Dr. Morton reports being a consultant for Vibrynt and Ethicon.
American Society for Metabolic and Bariatric Surgery (ASMBS) 29th Annual Meeting: Abstract PL 103. Presented June 20, 2012.


Monday, July 9, 2012

An Endocrinologist Talks about Hypoglycemia after Gastric Bypass

Post-gastric bypass hypoglycemia: A serious complication of bariatric surgery | Endocrine Today:


Post-gastric bypass hypoglycemia: A serious complication of bariatric surgery

  • Endocrine Today, November 2010
    Dawn Belt Davis, MD, PhD
Obesity is a rapidly increasing problem in the United States and worldwide, with more than 30% of adult Americans now affected. Unfortunately, we are lacking in effective therapies to promote significant weight loss.
Although aggressive lifestyle modification is highly effective, it is plagued by difficulties with poor compliance, access and reimbursement. Medical therapy for obesity has limited efficacy and significant side effects, and with the recent withdrawal of sibutramine from the US market, there are limited options (See more info on this here). Therefore, more patients and providers are turning to bariatric surgery for the treatment of obesity and its comorbidities. Especially in the case of Roux-en-Y gastric bypass surgery, this is a highly effective therapy that can lead to significant weight loss and also improve metabolic parameters independent of weight loss.
Dawn Belt Davis, MD, PhD
Dawn Belt Davis
Roux-en-Y gastric bypass surgery involves attaching a small pouch of the upper stomach to the early part of the jejunum, thereby bypassing the majority of the stomach and the duodenum. This results in an increased sense of fullness and reduction in appetite, as well as alterations in hormonal release from the small intestine in response to food. This procedure has been found to lead to resolution of type 2 diabetes in up to 80% of patients. It has therefore been proposed as a potential “cure” for type 2 diabetes.
Evaluating risks of surgery
As with any therapy, Roux-en-Y gastric bypass surgery can result in adverse effects and complications. Although the immediate risks of morbidity and mortality from the surgery are low, the long-term risks associated with malabsorption and other complications are still being clarified as an increasing number of patients are undergoing this procedure.
One long-term risk is the development of postprandial hypoglycemia. This phenomenon was first described in the literature in 2005. The prevalence still remains unknown, but as endocrinologists we will undoubtedly be seeing more of these patients. Hypoglycemia typically does not present until 2 to 3 years after gastric bypass surgery. These hypoglycemic episodes are characterized by low blood sugars that occur 2 to 3 hours after a meal. Fasting hypoglycemia is typically not seen. The etiology seems to be excessive insulin secretion in response to the meal. It is well documented that patients are more insulin sensitive after gastric bypass surgery, but the pathophysiology of these specific patients who develop hypoglycemia remains unclear. It is hypothesized that it may be related to elevations in the incretin hormones glucagon-like peptide 1 and gastric inhibitory polypeptide, and their ability to stimulate additional insulin secretion. It has also been debated whether increased beta-cell mass may lead to excessive insulin secretion.
Unfortunately, the effect of this disorder on the lives of patients can be devastating and severe. They become trapped in a vicious cycle in which the very treatment of their hypoglycemia leads to yet another episode a few hours later. Hypoglycemic unawareness can develop relatively rapidly, as these patients may have several episodes per day. Patients can have loss of consciousness and seizures, which may result in motor vehicle accidents. Many patients go undiagnosed for extended periods of time, as there is limited awareness of this disorder in the medical community and the initial episodes are often mild with subtle symptoms.
There are limited resources to determine the appropriate treatment strategy for these patients, with most studies reporting only a small number of cases.
First-line treatment should be educating the patient to follow a diet with strict avoidance of high-glycemic-index carbohydrates and limited portions of any carbohydrate. In addition, acarbose (Precose, Bayer Pharmaceuticals) is often successful in patients with relatively mild disease to reduce carbohydrate absorption. In patients who do not respond to these initial therapies, the addition of medications to antagonize insulin activity or minimize insulin secretion can be helpful. Calcium-channel blockers, octreotide or diazoxide are other options that can be tried. In the most severe patients, partial pancreatectomy has been performed; unfortunately, it has not been universally successful at reversing the hypoglycemic episodes. It is unknown if reversal of the gastric bypass is a successful strategy.
Fostering awareness
As endocrinologists, we need to be aware of this complication and ask about symptoms in all patients after gastric bypass surgery. In my experience, many patients have been struggling to self-manage these symptoms and are relieved to learn that this is a recognized complication and treatment options exist. Many patients respond well to dietary modification and acarbose alone. Those patients with the most severe and difficult to control symptoms are challenging. Surgical options should be considered as a last resort, as their effectiveness is unclear and there is obvious associated morbidity. Ongoing research efforts continue to determine the underlying etiology of this disorder and therapeutic options, including nutritional, pharmacologic and surgical approaches.
In the meantime, treatment of these challenging patients requires a bit of creativity, good communication with the patient and the rest of the care team (nutritionists, bariatric surgeons and gastroenterologists), and attention to the latest advances in the literature. Most importantly, we will need to further determine the frequency of this complication and carefully consider this when we weigh the risks and benefits of Roux-en-Y gastric bypass procedures.
With an increasing number of these procedures being performed every year and with a recent push to consider this procedure as a curative therapy for type 2 diabetes, it is crucial to learn more about this serious complication so we can educate patients about the risks and hopefully identify those at highest risk before the procedure.
Dawn Belt Davis, MD, PhD, is an assistant professor in the section of endocrinology, diabetes and metabolism at the University of Wisconsin-Madison and is a member of the Endocrine Today Editorial Board.



'via Blog this'